Assessment of rapid remobilization intervals with G-CSF and SCF in murine and rhesus macaque models

被引:8
作者
Shi, PA
Pomper, GJ
Metzger, ME
Donahue, RE
Leitman, SF
Dunbar, CE
机构
[1] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Dept Transfus Med, Bethesda, MD USA
关键词
D O I
10.1046/j.1537-2995.2001.41111438.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Defining the optimum regimen and time for repeat peripheral blood progenitor cell mobilization would have important clinical applications. STUDY DESIGN AND METHODS: Remobilization with SCF and G-CSF at 2 weeks after an initial mobilization in mice and at 2 or 4 weeks after an initial mobilization in nonhuman primates was examined. In mice, competitive repopulation assays were used to measure long-term progenitor cell-repopulating activity. In monkeys, mobilization of hematopoietic progenitor CFUs was used as a surrogate marker for progenitor cell-repopulating ability. RESULTS: Efficacy of progenitor cell remobilization differed in the two animal species. In mice, peripheral blood progenitor cell-repopulating ability with repeat mobilization at 2 weeks was 70 percent of that with the initial mobilization. In monkeys, there was no significant difference in peripheral blood progenitor cell mobilization between the initial and the repeat mobilizations at 2 weeks. In mobilizations separated by 4 weeks, however, peripheral blood progenitor cell mobilization was higher than that with initial mobilizations. CONCLUSION: In animal models, mobilization of peripheral blood progenitor cells with remobilization after a 2-week interval is similar to or moderately decreased from that with the initial mobilization. Progenitor cell collection at this time point may be useful in certain clinical circumstances. A 4-week interval between remobilizations may be preferable, Clinical trials in humans would be useful to clarify these issues.
引用
收藏
页码:1438 / 1444
页数:7
相关论文
共 42 条
[1]   Peripheral blood stem cell apheresis in normal donors: Feasibility and yield of second collections [J].
Anderlini, P ;
Lauppe, J ;
Przepiorka, D ;
Seong, D ;
Champlin, R ;
Korbling, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (02) :415-417
[2]  
Anderlini P, 1997, TRANSFUSION, V37, P109
[3]   Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype [J].
Aversa, F ;
Tabilio, A ;
Velardi, A ;
Cunningham, I ;
Terenzi, A ;
Falzetti, F ;
Ruggeri, L ;
Barbabietola, G ;
Aristei, C ;
Latini, P ;
Reisner, Y ;
Martelli, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) :1186-1193
[4]  
BACIGALUPO A, 1995, BONE MARROW TRANSPL, V15, P221
[5]   Bone marrow or peripheral blood as a source of stem cells for allogeneic transplants [J].
Bacigalupo, A ;
Frassoni, F ;
Van Lint, MT .
CURRENT OPINION IN HEMATOLOGY, 2000, 7 (06) :343-347
[6]  
Bahçeci E, 2000, BRIT J HAEMATOL, V108, P408
[7]   Total therapy with tandem transplants for newly diagnosed multiple myeloma [J].
Barlogie, B ;
Jagannath, S ;
Desikan, KR ;
Mattox, S ;
Vesole, D ;
Siegel, D ;
Tricot, G ;
Munshi, N ;
Fassas, A ;
Singhal, S ;
Mehta, J ;
Anaissie, E ;
Dhodapkar, D ;
Naucke, S ;
Cromer, J ;
Sawyer, J ;
Epstein, J ;
Spoon, D ;
Ayers, D ;
Cheson, B ;
Crowley, J .
BLOOD, 1999, 93 (01) :55-65
[8]  
Barrett AJ, 2000, BLOOD, V95, P3323
[9]   Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. [J].
Bensinger, WI ;
Martin, PJ ;
Storer, B ;
Clift, R ;
Forman, SJ ;
Negrin, R ;
Kashyap, A ;
Flowers, MED ;
Lilleby, K ;
Chauncey, TR ;
Storb, R ;
Appelbaum, FR ;
Rowley, S ;
Heimfeld, S ;
Blume, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) :175-181
[10]  
Bodine DM, 1996, BLOOD, V88, P89